
plethysmographic measurements after 6-month treatment. However, comparison vs placebo in another 3month trial294 failed to show a signiﬁcant difference for
edema, symptoms of CVD, and QOL, with exception of
QOL at 12-month follow-up, better in calcium dobesilate
group. A more recent trial with calcium dobesilate vs
MPFF295 reported similar and signiﬁcant pain reduction
in